重组干扰素α-2b治疗小儿呼吸道合胞病毒毛细支气管炎对肺表面活性蛋白D和转化生长因子-β的影响  

Effect of recombinant interferon α-2b on pulmonary surfactant protein D and transforming growth factor-β in the treatment of pediatric respiratory syncytial virus bronchiolitis

作　　者：郑兰 ZHENG Lan(Department of Pediatrics,the First People's Hospital of Jinzhou District,Dalian,Liaoning,116100,China)

机构地区：[1]大连市金州区第一人民医院儿科,辽宁大连116100

出　　处：《当代医学》2023年第14期83-86,共4页Contemporary Medicine

摘　　要：目的探讨重组干扰素α-2b治疗小儿呼吸道合胞病毒毛细支气管炎对肺表面活性蛋白D(SP-D)、转化生长因子-β(TGF-β)的影响。方法选取2019年3月至2020年10月于本院儿科就诊的174例呼吸道合胞病毒所致的毛细支气管炎患儿作为研究对象,按照随机数字表法分为对照组与观察组,每组87例。对照组给予布地奈德混悬液联合孟鲁司特钠治疗,观察组在对照组基础上增加重组人干扰素α-2b治疗,比较两组临床疗效、临床症状消失时间及住院时间、实验室指标(SP-D、TGF-β)及不良反应发生率。结果观察组治疗总有效率为96.55%,高于对照组的88.51%,差异有统计学意义(P<0.05)。观察组喘憋消失时间、肺部湿啰音消失时间、咳嗽消失时间及住院时间均短于对照组,差异有统计学意义(P<0.05)。治疗前,两组SP-D、TGF-β水平比较差异无统计学意义;治疗7 d后,两组SP-D水平低于治疗前,TGF-β水平高于治疗前,且观察组SP-D水平低于对照组,TGF-β水平高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论重组干扰素α-2b治疗小儿呼吸道合胞病毒致毛细支气管炎疗效显著,有助于加快缓解患儿临床症状,降低SP-D水平,提高TGF-β水平,且安全性较高,值得临床推广应用。Objective To investigate the effects of recombinant interferonα-2b on pulmonary surfactant protein D(SP-D)and transforming growth factor-β(TGF-β)in the treatment of pediatric respiratory syncytial virus(RSV)bronchiolitis.Methods 174 children diagnosed with pediatric RSV bronchiolitis and treated in the Pediatric department of our hospital from March 2019 to October 2020 were selected as the study subjects,and they were divided into the control group and the observation group according to the random number table method,with 87 cases in each group.The control group was treated with budesonide suspension combined with montelukast sodium,and the observation group was treated with recombinant human interferonα-2b on the basis of the control group,the clinical efficacy,clinical symptoms disappeared time and length of hospital stay,laboratory indicators(SP-D,TGF-β)and the incidence of adverse reactions were compared between the two groups.Results The total effective rate in the observation group was 96.55%,which was higher than 88.51%in the control group,and the difference was statistically significant(P<0.05).The disappearance time of asthma,lung moist rales,cough and hospital stay in the observation group were shorter than the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of SP-D and TGF-βbetween the two groups;after 7 d of treatment,SP-D level of the two groups lower than before treatment,TGF-βlevel was higher than before treatment,and SP-D level in the observation group was lower than the control group,TGF-βlevel was higher than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Recombinant interferdoi onα-2b is effective in the treatment of bronchiolitis caused by respiratory syncytial virus in children,it can accelerate the relief of clinical symptoms in children,reduce the level of SP

关 键 词：呼吸道合胞病毒 小儿毛细支气管炎 重组干扰素Α-2B 肺表面活性蛋白D 转化生长因子-Β 

分 类 号：R725.6[医药卫生—儿科]